Skip to search.
 TSX Up0.08% TSX Ventures 0.00%

More On VRX.TO

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


Valeant Pharmaceuticals International Inc (VRX.TO)

-Toronto

77.66 Up 0.14(0.18%) May 22, 4:00PM EDT

Add to Portfolio
ProfileGet Profile for:
Valeant Pharmaceuticals International Inc
4787 Levy Street
Montreal, QC H4R 2P9
Canada - Map
Phone: 514-744-6792
Fax: 514-744-6272
Website: http://www.valeant.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drugs - Generic
Full Time Employees:7,000

Business Summary 

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. It offers dermatology products, such as Zovirax Ointment, Xerese, Retin-A Micro, Elidel, Carac, Acanya gel, Sculptra and Sculptra Aesthetic, Atralin, Solodyn, Zyclara, Ziana, Vanos, Restylane family of products, and Dysport; over-the-counter (OTC) products, including CeraVe and AcneFree; dentistry products, such as Arestin and Teeth Whitening System; ophthalmology products, including Timoptic, Timoptic, Macugen, and Visudyne; and neurology and other products, such as Wellbutrin XL and Xenazine in the United States. The company also provides pharmaceutical products, including Tiazac XC, Wellbutrin XL, Zovirax, Benzaclin, and Penlac; and Cold-FX, an OTC product in Canada, as well as Duromine/Metermine, Difflam, Duro-Tuss, and Rikodeine in Australia. In addition, it offers a range of treatments, including antibiotics, treatments for cardiovascular and neurological diseases, dermatological products, and diabetic therapies, as well as a range of various OTC products in Europe; and products for a range of therapeutic classes, including vitamin deficiency, antibacterials, and dermatology in Mexico and Brazil. Further, the company provides Duromine, Andolex, and Pholtex products in South Africa; and Difflam, Duro-Tuss, Tambocor, and Norgesic in Asia. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Mississauga, Canada.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Valeant Pharmaceuticals International Inc

Key Executives 
 PayExercised
Mr. J. Michael Pearson , 53
Chairman and Chief Exec. Officer
6.11M0.00
Mr. Howard Bradley Schiller , 51
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Director
2.41M0.00
Mr. Ryan H. Weldon , 35
Group Chairman of The U.S. Dermatology Operations and Exec. VP
503.00k0.00
Mr. Jason D. Hanson , 44
Consultant
37.00k0.00
Mr. Christopher Bovaird , 53
VP of Corp. Fin.
N/AN/A
Amounts are as of 2012-12-30 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.